Chronic Myeloproliferative Syndromes (non-CML)

Internal Medicine · Clinical Specialties

How it begins

Análisis exhaustivo de las neoplasias mieloproliferativas crónicas BCR-ABL1 negativas: Policitemia Vera, Trombocitemia Esencial, Mielofibrosis Primaria, Mastocitosis Sistémica y entidades relacionadas. Bases moleculares, criterios diagnósticos WHO 2022, estratificación de riesgo, tratamiento basado en evidencia y correlaciones clínicas de nivel experto.

What it covers

1. · Chronic Myeloproliferative Syndromes
2. Concept, History and WHO Classification 2022
3. · WHO 2022 Classification of Myeloproliferative Neoplasms
4. · General Molecular Pathogenesis: JAK-STAT Signaling
5. Polycythemia Vera (PV)
6. · 2.1 Pathogenesis: JAK2 and Hypersensitivity to EPO
7. · 2.2 Clinical Manifestations
8. · 2.3 Diagnosis: WHO 2022 Criteria
9. · 2.4 Treatment of Polycythemia Vera
10. Essential Thrombocythemia (ET)
11. · 3.1 Driver Mutations and Biological Heterogeneity
12. · 3.2 Clinical Manifestations
13. · 3.3 Diagnosis: WHO 2022 Criteria
14. · 3.4 Risk Stratification and Treatment
15. Primary Myelofibrosis (MFP)
16. · 4.1 Pathogenesis: Fibrosis and Extramedullary Hematopoiesis
17. · 4.2 Clinical Manifestations and Diagnosis
18. · WHO 2022 Diagnostic Criteria for MFP
19. · 4.3 Prognostic Scoring Systems
20. · 4.4 Treatment of Myelofibrosis
21. Systemic Mastocytosis (SM)
22. · 5.1 Classification and Clinical
23. · 5.2 Treatment of Systemic Mastocytosis
24. Chronic Myelomonocytic Leukemia (CMML)
25. · 6.1 Classification and Characteristics
26. · 6.2 Mutations and Pathogenesis
27. · 6.3 Treatment of CMML
28. MPN with Eosinophilia and Specific Genetic Rearrangements
29. Thrombotic and Hemorrhagic Complications in MPN
30. · 8.1 Pathophysiology of Thrombosis in NMP
31. · 8.2 Antithrombotic Strategy in MPN
32. · 8.3 Leukemic Transformation (AML)
33. MPN and Pregnancy: Specialized Management
34. · 9.1 TE in Pregnancy
35. · 9.2 PV in Pregnancy
36. Global Comparative Table of non-LMC NMP
37. Emerging Targeted Therapies and Perspectives
38. · 11.1 BET (Bromodomain and Extra-Terminal) Inhibitors
39. · 11.2 Telomerase Inhibitors (Imetelstat)
40. · 11.3 Venetoclax (BCL-2 inhibitor) in NMP
41. · 11.4 Luspatercept in MFP Anemia
42. · 11.5 Navitoclax (BCL-XL inhibitor) + Ruxolitinib
43. · 11.6 Inhibition of the PI3K-AKT-mTOR Pathway